Voyageur Pharmaceuticals Ltd. SEDAR Filings

Voyageur Pharmaceuticals Ltd. announced a non-brokered private placement for aggregate gross proceeds of a minimum of $4,000,000 and a maximum of $7,500,000

Material change report - English.pdf

Results 2026-03-27 Financials

Open PDF

Annual MD&A - English.pdf

Results 2026-03-27 Financials

Open PDF

Audited annual financial statements – English.pdf

News 2026-03-25

Offering document - English.pdf

Transactions 2026-03-25 Financing

Open PDF

VOYAGEUR ANNOUNCES NON-BROKERED LIFE OFFERING

News release - English.pdf

News 2026-03-16

Open PDF

Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects

News release - English.pdf

News 2026-03-04

Open PDF

Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt

News release - English.pdf

News 2026-03-02

Open PDF

Voyageur Pharmaceuticals Announces Entering Into of a Collaboration and Funding Agreement with Bayer

Material change report - English.pdf

Transactions 2026-02-23 M&A

Open PDF

Voyageur Pharmaceuticals Announces Collaboration with Bayer

News release - English.pdf

Transactions 2026-01-20 M&A

Open PDF

Voyageur Pharmaceuticals announced the appointment of Dr. Brian Mueller as Director of Chemistry and the acquisition of 100% ownership of his proprietary iodine extraction technology.

Material change report - English.pdf

Transactions 2026-01-12 M&A

Open PDF

Voyageur Pharmaceuticals Acquires Exclusive Ownership of Iodine Extraction Technology and Strengthens Scientific Team with Dr. Brian Mueller

News release - English.pdf

News 2025-11-07

Open PDF

News release - English.pdf

News 2025-10-29

Open PDF

News release - English.pdf

Results 2025-10-27 Financials